Novel delivery methods bypassing the blood-brain and blood-tumor barriers

Neurosurgical Focus

Volumn 38, Issue 3, 2015, Pages

  Hendricks, Benjamin K ^a   Cohen Gadol, Aaron A ^a,b   Miller, James C ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Blood tumor barrier; Gliadel; Glioblastoma; Liposome; Mannitol; Nanoparticle; Stem cell; Thermotherapy; Ultrasound

Indexed keywords

BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS;

EID: 84929617636     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2015.1.FOCUS14767     Document Type: Article

References (186)

1. Abbott NJ: Astrocyte-endothelial interactions and bloodbrain barrier permeability. J Anat 200:629-638, 2002.
2. Abbott NJ: Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36:437-449, 2013.
3. Abbott NJ, Rönnbäck L, Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53, 2006.
4. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D: The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95:1201-1214, 2005.
5. Acerbi F, Broggi M, Eoli M, Anghileri E, Cavallo C, Boffano C, et al: Is fluorescein-guided technique able to help in resection of high-grade gliomas?. Neurosurg Focus 36:E5, 2014.
6. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF: Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17, 2011.
7. Agarwala SS, Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5:144-151, 2000.
8. Aleynik A, Gernavage KM, Mourad YSh, Sherman LS, Liu K, Gubenko YA, et al: Stem cell delivery of therapies for brain disorders. Clin Transl Med 3:24, 2014.
9. Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, Mravec B, et al: Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase:uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 130:2455-2463, 2012.
10. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, et al: Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27:3503-3509, 2009.
11. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al: Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887-2893, 2008.
12. Barua NU, Hopkins K, Woolley M, O'Sullivan S, Harrison R, Edwards RJ, et al: A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv [epub ahead of print], 2014.
13. Becker KP, Yu J: Status quo-standard-of-care medical and radiation therapy for glioblastoma. Cancer J 18:12-19, 2012.
14. Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, et al: Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine (Lond Print) 10:149-157, 2014.
15. Betz AL: Transport of ions across the blood-brain barrier. Fed Proc 45:2050-2054, 1986.
16. Birngruber T, Raml R, Gladdines W, Gatschelhofer C, Gander E, Ghosh A, et al: Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,®/Doxil®-a cerebral open flow microperfusion pilot study. J Pharm Sci 103:1945-1948, 2014.
17. Black KL, Chio CC: Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. Neurol Res 14:402-404, 1992.
18. Black P, Hand CM, Vender JR, Finkelstein SD: Chemotherapy in experimental brain tumor, part 2: pretreatment with leukotriene C4 prolongs survival. J Neurooncol 36:7-19, 1998.
19. Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM: Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem 24:1741-1749, 2013.
20. Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM: Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng 110:1456-1465, 2013.
21. Boado RJ, Pardridge WM: Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos 37:2299-2304, 2009.
22. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al: Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132-142, 2011.
23. Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, et al: Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 114:624-632, 2011.
24. Breedveld P, Beijnen JH, Schellens JH: Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24, 2006.
25. Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, et al: The role of Gliadel wafers in the treatment of highgrade gliomas. Expert Rev Anticancer Ther 13:1453-1461, 2013.
26. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26:5603-5609, 2008.
27. Burkhardt JK, Hofstetter CP, Santillan A, Shin BJ, Foley CP, Ballon DJ, et al: Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench. J Clin Neurosci 19:1568-1572, 2012.
28. Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, et al: Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 77:130-134, 2012.
29. Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA: Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 17:286-295, 2011.
30. Burkhardt JK, Santillan A, Hofstetter CP, Christos P, Berry N, Shin BJ, et al: Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model. J Exp Ther Oncol 10:31-37, 2012.
31. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, et al: Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A 107:20021-20026, 2010.
32. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, et al: Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 57:34-39, 2006.
33. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, et al: Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8:60-66, 2006.
34. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M, et al: Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12:401-408, 2010.
35. Charest G, Sanche L, Fortin D, Mathieu D, Paquette B: Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. J Neurooncol 115:365-373, 2013.
36. Charles N, Holland EC: The perivascular niche microenvironment in brain tumor progression. Cell Cycle 9:3012-3021, 2010.
37. Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, et al: Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomidechemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Ann Oncol 25:1442-1447, 2014.
38. Chen H, Konofagou EE: The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J Cereb Blood Flow Metab 34:1197-1204, 2014.
39. Cheng L, Bao S, Rich JN: Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80:654-665, 2010.
40. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al: Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139-152, 2013.
41. Chiu TL, Lin SZ, Hsieh WH, Peng CW: AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int J Oncol 35:1361-1367, 2009.
42. Choi JJ, Wang S, Tung YS, Morrison B III, Konofagou EE: Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med Biol 36:58-67, 2010.
43. Ciordia R, Supko J, Gatineau M, Batchelor T: Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr Oncol Rep 2:445-453, 2000.
44. Clarke JL: Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 18:328-342, 2012.
45. Cloughesy TF, Black KL: Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26:125-132, 1995.
46. Côté J, Bovenzi V, Savard M, Dubuc C, Fortier A, Neugebauer W, et al: Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PLoS ONE 7:e37485, 2012.
47. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, et al: Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:259-267, 2008.
48. da Fonseca CO, Teixeira RM, Silva JC, DE Saldanha DA Gama Fischer J, Meirelles OC, Landeiro JA, et al: Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation. Anticancer Res 33:5625-5631, 2013.
49. Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, et al: Implanted system for intraventricular drug infusion in central nervous system tumors. Cancer Treat Rep 65:401-411, 1981.
50. de Groot J, Sontheimer H: Glutamate and the biology of gliomas. Glia 59:1181-1189, 2011.
51. Deo AK, Theil FP, Nicolas JM: Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm 10:1581-1595, 2013.
52. Di Ieva A, Grizzi F, Sherif C, Matula C, Tschabitscher M: Angioarchitectural heterogeneity in human glioblastoma multiforme: a fractal-based histopathological assessment. Microvasc Res 81:222-230, 2011.
53. Dietrich J, Imitola J, Kesari S: Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 5:393-404, 2008.
54. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, et al: Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 19:1567-1576, 2013.
55. Dropcho EJ, Rosenfeld SS, Vitek J, Guthrie BL, Morawetz RB: Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 36:191-198, 1998.
56. Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, et al: Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst 106:dju090, 2014.
57. Elliott PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT: Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 56:3998-4005, 1996.
58. Erdlenbruch B, Schinkhof C, Kugler W, Heinemann DE, Herms J, Eibl H, et al: Intracarotid administration of shortchain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol 139:685-694, 2003.
59. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, et al: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942, 2001.
60. Farrington GK, Caram-Salas N, Haqqani AS, Brunette E, Eldredge J, Pepinsky B, et al: A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J 28:4764-4778, 2014.
61. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, et al: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318, 2002.
62. Foley CP, Rubin DG, Santillan A, Sondhi D, Dyke JP, Pierre Gobin Y, et al: Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J Control Release 196:71-78, 2014.
63. Ford J, Osborn C, Barton T, Bleehen NM: A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34:1807-1811, 1998.
64. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 103:2606-2615, 2005.
65. Fortin D, Gendron C, Boudrias M, Garant MP: Enhanced chemotherapy delivery by intraarterial infusion and bloodbrain barrier disruption in the treatment of cerebral metastasis. Cancer 109:751-760, 2007.
66. French JD, West PM, Von Amerongen FK, Magoun HW: Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg 9:378-389, 1952.
67. Fry M, Ferguson AV: The sensory circumventricular organs: brain targets for circulating signals controlling ingestive behavior. Physiol Behav 91:413-423, 2007.
68. Ghersi-Egea JF, Finnegan W, Chen JL, Fenstermacher JD: Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 75:1271-1288, 1996.
69. Goldwirt L, Beccaria K, Carpentier A, Farinotti R, Fernandez C: Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol 74:185-193, 2014.
70. Gonzales-Portillo GS, Sanberg PR, Franzblau M, Gonzales-Portillo C, Diamandis T, Staples M, et al: Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier. Cell Transplant 23:531-539, 2014.
71. Grant R, Walker M, Hadley D, Barton T, Osborn C: Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 57:241-245, 2002.
72. Greco SJ, Rameshwar P: Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Ther Deliv 3:997-1004, 2012.
73. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2:45-59, 2000.
74. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA: Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery 66:48-58, 2010.
75. Gutman M, Laufer R, Eisenthal A, Goldman G, Ravid A, Inbar M, et al: Increased microvascular permeability induced by prolonged interleukin-2 administration is attenuated by the oxygen-free-radical scavenger dimethylthiourea. Cancer Immunol Immunother 43:240-244, 1996.
76. Hanson LR, Frey WH II: Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9 (Suppl 3):S5, 2008.
77. Harding TC, Lalani AS, Roberts BN, Yendluri S, Luan B, Koprivnikar KE, et al: AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Ther 13:956-966, 2006.
78. Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR: Opening the blood-brain and bloodtumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol 19:50-59, 1986.
79. Horn AP, Bernardi A, Luiz Frozza R, Grudzinski PB, Hoppe JB, de Souza LF, et al: Mesenchymal stem cell-conditioned medium triggers neuroinflammation and reactive species generation in organotypic cultures of rat hippocampus. Stem Cells Dev 20:1171-1181, 2011.
80. Huang J, Yuan D, Liu D, Li J, Li Y, Hall WA, et al: Efficacy of antiangiogenic targeted immunotoxin DTAT and DTATEGF against glioblastoma multiforme. Zhong Nan Da Xue Xue Bao Yi Xue Ban 39:1-5, 2014.
81. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA: Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640-646, 2001.
82. Ikeda M, Nagashima T, Bhattacharjee AK, Kondoh T, Kohmura E, Tamaki N: Quantitative analysis of hyperosmotic and hypothermic blood-brain barrier opening. Acta Neurochir Suppl 86:559-563, 2003.
83. Inamura T, Black KL: Bradykinin selectively opens bloodtumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14:862-870, 1994.
84. Inoue T, Fukui M, Nishio S, Kitamura K, Nagara H: Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J Neurosurg 66:256-263, 1987.
85. Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, et al: Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 112:581-588, 2008.
86. Jain RK, Munn LL, Fukumura D: Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2:266-276, 2002.
87. Jiang G, Jiang AJ, Xin Y, Li LT, Cheng Q, Zheng JN: Progression of O6-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. Mol Biol Rep 41:6659-6665, 2014.
88. Johanson CE, Duncan JA III, Klinge PM, Brinker T, Stopa EG, Silverberg GD: Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 5:10, 2008.
89. Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, et al: Efficient delivery of liposome-mediated MGMTsiRNA reinforces the cytotoxity of temozolomide in GBMinitiating cells. Gene Ther 17:1363-1371, 2010.
90. Kinoshita M, McDannold N, Jolesz FA, Hynynen K: Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced bloodbrain barrier disruption. Proc Natl Acad Sci U S A 103:11719-11723, 2006.
91. Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV: Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 17:2088-2095, 2009.
92. Konofagou EE: Optimization of the ultrasound-induced blood-brain barrier opening. Theranostics 2:1223-1237, 2012.
93. Kovacs Z, Werner B, Rassi A, Sass JO, Martin-Fiori E, Bernasconi M: Prolonged survival upon ultrasoundenhanced doxorubicin delivery in two syngenic glioblastoma mouse models. J Control Release 187:74-82, 2014.
94. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, et al: Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 9:393-403, 2007.
95. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al: Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871-881, 2010.
96. Larner JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA: A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. Am J Clin Oncol 18:1-7, 1995.
97. Larsen JM, Martin DR, Byrne ME: Recent advances in delivery through the blood-brain barrier. Curr Top Med Chem 14:1148-1160, 2014.
98. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al: Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget 4:346-361, 2013.
99. Lee Titsworth W, Murad GJ, Hoh BL, Rahman M: Fighting fire with fire: the revival of thermotherapy for gliomas. Anticancer Res 34:565-574, 2014.
100. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al: Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621, 2004.
101. Lei C, Cui Y, Zheng L, Chow PK, Wang CH: Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects. Biomaterials 34:7483-7494, 2013.
102. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, et al: Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100:323-331, 2000.
103. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26, 2001.
104. Lopez-Ramirez MA, Fischer R, Torres-Badillo CC, Davies HA, Logan K, Pfizenmaier K, et al: Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells. J Immunol 189:3130-3139, 2012.
105. Lv H, Zhang S, Wang B, Cui S, Yan J: Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114:100-109, 2006.
106. Madane RG, Mahajan HS: Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv [epub ahead of print], 2014.
107. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, et al: Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165:601-608, 2004.
108. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, et al: Extensive distribution of liposomes in rodent brains and brain tumors following convectionenhanced delivery. J Neurooncol 68:1-9, 2004.
109. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39:125-134, 1996.
110. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS: Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652-3663, 2012.
111. Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, et al: Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med 2:983-992, 2013.
112. Montana V, Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 31:4858-4867, 2011.
113. Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, et al: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for deliv-ery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol 147:1840-1851, 1995.
114. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al: Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295-2305, 2007.
115. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P: Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 2:e126, 2013.
116. Munoz JL, Rodriguez-Cruz V, Greco SJ, Nagula V, Scotto KW, Rameshwar P: Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol Cancer Ther 13:2399-2411, 2014.
117. Namba H, Kobayashi S, Iwadate Y, Saegusa T, Sato A, Watanabe Y, et al: Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime-technical note. Neurol Med Chir (Tokyo) 34:832-835, 1994.
118. Navalitloha Y, Schwartz ES, Groothuis EN, Allen CV, Levy RM, Groothuis DR: Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro Oncol 8:227-233, 2006.
119. Neuwelt EA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, et al: Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery. Trans Am Neurol Assoc 104:256-260, 1979.
120. Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, et al: Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Cancer Treat Rep 65 (Suppl 2):39-43, 1981.
121. Noell S, Ritz R, Wolburg-Buchholz K, Wolburg H, Fallier-Becker P: An allograft glioma model reveals the dependence of aquaporin-4 expression on the brain microenvironment. PLoS ONE 7:e36555, 2012.
122. Ogunshola OO, Al-Ahmad A: HIF-1 at the blood-brain barrier: a mediator of permeability?. High Alt Med Biol 13:153-161, 2012.
123. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE: Chemoradiotherapy for primary CNS lymphoma: an intentto-treat analysis with complete follow-up. Neurology 64:69-74, 2005.
124. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728-3736, 2004.
125. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16 (Suppl 4):iv1-iv63, 2014.
126. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN: Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28:1882-1893, 2008.
127. Papisov MI, Belov VV, Gannon KS: Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm 10:1522-1532, 2013.
128. Pardridge WM: Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32:1959-1972, 2012.
129. Postmes TJ, Hukkelhoven M, van den Bogaard AE, Halders SG, Coenegracht J: Passage through the blood-brain barrier of thyrotropin-releasing hormone encapsulated in liposomes. J Pharm Pharmacol 32:722-724, 1980.
130. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401, 2000.
131. Reagan MR, Kaplan DL: Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 29:920-927, 2011.
132. Reiber H, Felgenhauer K: Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 163:319-328, 1987.
133. Reitz M, Demestre M, Sedlacik J, Meissner H, Fiehler J, Kim SU, et al: Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med 1:866-873, 2012.
134. Ren H, Boulikas T, Lundstrom K, Söling A, Warnke PC, Rainov NG: Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replicationincompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol 64:147-154, 2003.
135. Rodriguez-Cruz V, Munoz JL, Rameshwar P: CB-07. Mechanisms of chemoresistance in CD133-expressing glioblastoma cells: the role of drug efflux transporters. Neuro Oncol 14 (Suppl 6):vi87, 2012 (Abstract).
136. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, et al: Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572-2579, 2004.
137. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, et al: Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convectionenhanced delivery in the primate brain. Exp Neurol 196:381-389, 2005.
138. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, et al: Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 20(2):E14, 2006.
139. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, et al: Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 7:51, 2009.
140. Sathornsumetee S, Rich JN: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 6:1087-1104, 2006.
141. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, et al: Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res 1:34-42, 2011.
142. Schebesch KM, Proescholdt M, Höhne J, Hohenberger C, Hansen E, Riemenschneider MJ, et al: Sodium fluoresceinguided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery-a feasibility study. Acta Neurochir (Wien) 155:693-699, 2013.
143. Schlageter KE, Molnar P, Lapin GD, Groothuis DR: Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 58:312-328, 1999.
144. Seifert S, Sontheimer H: Bradykinin enhances invasion of malignant glioma into the brain parenchyma by inducing cells to undergo amoeboid migration. J Physiol 592:5109-5127, 2014.
145. Shin BJ, Burkhardt JK, Riina HA, Boockvar JA: Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 23:323-329, ix-x, 2012.
146. Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, et al: Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol 16:1210-1219, 2014.
147. Squire LR, Bloom FE, Spitzer NC, du Lac S, Ghosh A, Berg D: Fundamental Neuroscience, ed 3. Boston: Elsevier, 2008.
148. Strazielle N, Ghersi-Egea JF: Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 10:1473-1491, 2013.
149. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005.
150. Tate MC, Aghi MK: Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6:447-457, 2009.
151. Teng J, Hejazi S, Badr CE, Tannous BA: Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells 32:2021-2032, 2014.
152. Theodotou C, Shah AH, Hayes S, Bregy A, Johnson JN, Aziz-Sultan MA, et al: The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. Br J Neurosurg 28:438-446, 2014.
153. Thévenot E, Jordão JF, O'Reilly MA, Markham K, Weng YQ, Foust KD, et al: Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum Gene Ther 23:1144-1155, 2012.
154. Thomas AA, Brennan CW, DeAngelis LM, Omuro AM: Emerging therapies for glioblastoma. JAMA Neurol 71:1437-1444, 2014.
155. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K: Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901-907, 2007.
156. Tros de Ilarduya C, Sun Y, Düzgüneş N: Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40:159-170, 2010.
157. Tsujiuchi T, Natsume A, Motomura K, Kondo G, Ranjit M, Hachisu R, et al: Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am J Transl Res 6:169-178, 2014.
158. van Deurs B, Koehler JK: Tight junctions in the choroid plexus epithelium. A freeze-fracture study including complementary replicas. J Cell Biol 80:662-673, 1979.
159. Vecil GG, Lang FF: Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65:237-246, 2003.
160. Vogelbaum MA: Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 73:57-69, 2005.
161. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, et al: Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:1031-1038, 2007.
162. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:479-487, 2003.
163. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829-833, 2010.
164. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, et al: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 58:343-347, 2006.
165. Warren KE, Patel MC, Aikin AA, Widemann B, Libucha M, Adamson PC, et al: Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 48:275-282, 2001.
166. Warth A, Mittelbronn M, Wolburg H: Redistribution of the water channel protein aquaporin-4 and the K+ channel protein Kir4.1 differs in low-and high-grade human brain tumors. Acta Neuropathol 109:418-426, 2005.
167. Watanabe M, Tanaka R, Hondo H, Kuroki M: Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells. Int J Hyperthermia 8:131-138, 1992.
168. Wei KC, Chu PC, Wang HY, Huang CY, Chen PY, Tsai HC, et al: Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS ONE 8:e58995, 2013.
169. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008.
170. White E, Bienemann A, Taylor H, Hopkins K, Cameron A, Gill S: A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp Clin Trials 33:320-331, 2012.
171. Whitin JC, Jang T, Merchant M, Yu TT, Lau K, Recht B, et al: Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model. PLoS ONE 7:e49724, 2012.
172. Winn HR: Youmans Neurological Surgery, ed 6. Philadelphia: Saunders, 2011.
173. Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME: Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 86:1347-1353, 1999.
174. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC: The blood-brain barrier: an engineering perspective. Front Neuroeng 6:7, 2013.
175. Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, et al: Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS ONE 5:e11074, 2010.
176. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, et al: Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol 9:20-28, 2007.
177. Yang FY, Horng SC: Chemotherapy of glioblastoma by targeted liposomal platinum compounds with focused ultrasound. Conf Proc IEEE Eng Med Biol Soc 2013:6289-6292, 2013.
178. Yang FY, Wang HE, Liu RS, Teng MC, Li JJ, Lu M, et al: Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound. PLoS ONE 7:e45468, 2012.
179. Yang W, Barth RF, Huo T, Nakkula RJ, Weldon M, Gupta N, et al: Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiat Oncol 9:25, 2014.
180. Yang Z, Xiang B, Dong D, Wang Z, Li J, Qi X: Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy. Curr Gene Ther 14:289-299, 2014.
181. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR: Tumortargeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35:5226-5239, 2014.
182. Yao L, Song Q, Bai W, Zhang J, Miao D, Jiang M, et al: Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubble-enhanced unfocused ultrasound. Biomaterials 35:3384-3395, 2014.
183. Yilmaz G, Vital S, Yilmaz CE, Stokes KY, Alexander JS, Granger DN: Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature. Stroke 42:806-811, 2011.
184. Youn P, Chen Y, Furgeson DY: A myristoylated cellpenetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol Pharm 11:486-495, 2014.
185. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, et al: Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139:13-22, 2013.
186. Zhou J, Atsina KB, Himes BT, Strohbehn GW, Saltzman WM: Novel delivery strategies for glioblastoma. Cancer J 18:89-99, 2012.